

**RWJUH Hamilton
2019 Patient Outcomes
Goals of the Oncology Program**

- To decrease the morbidity and mortality of patients with cancer.
- To improve the quality of patient care.
- To continue cancer control efforts.
- To enhance prevention and education.

Cancer Committee Members

Role	Name
Cancer Committee Chair	Dr. Maqsood Amjad
Cancer Liaison Physician	Dr. Firas Eladoumikdachi
Diagnostic Radiologist	Dr. Gurvan Blackman
Pathologist	Dr. Malik Deen
Medical Oncologist	Dr. Maqsood Amjad
Radiation Oncologist	Dr. Michael McKenna
Radiation Oncologist	Dr. Rachana Singh

Role	Name
Cancer Program Administrator	Tonya Davis, AVP
OP Oncology Nurse	Amy German, RN, OCN
IP Oncology Nurse	Lisa Nevius, RN, OCN
Certified Tumor Registrar	Stacy Yates, CTR
Social Worker	Roberta Weiner, MSW
Registered Dietician	Cindy Diamond Gottlieb
Clinical Research Coordinator	Lynn Glenn, RN, OCN
Genetic Professional	Sandra D'Elia, GCG
Palliative Care Team Member	Barbara Snyder, PhD
Pharmacist	Melikte Yohannes
Rehabilitation	Ketki Vyas
Pastoral Care Services	Chaplain Ted Taylor
American Cancer Society	Maureen Kuhn
Radiation Oncology	Kristen Greene
Breast Patient Navigator	Patty Hutman-Parker, RN
Lung Patient Navigator	Vivian Owusu-Mensah, APN
Tumor Registry Data Support	Joan Case
Quality Improvement Coordinator	Anna Lissa Lopez Stacy Yates / Dr. Rachana Singh
Quality Control Coordinator	
Community Outreach Coordinator	Lauren Stabinsky MSN
Cancer Conference Coordinator	Dr. Michael McKenna

Cancer Program

The Cancer Program at Robert Wood Johnson University Hospital Hamilton (RWJUHH) is dedicated to providing a full spectrum of cancer care services for the community. This commitment starts with the understanding that prevention and early detection is the key in our ongoing battle against cancer. Following the American Cancer Society (ACS) guidelines and the needs of our community based on the Mercer County Community Health Assessment; RWJUHH offered the following free Cancer Screenings Programs to the community in 2019:

- 9 Colorectal Screening
- 2 Prostate Screening

In addition, cancer related Prevention and Educational Programs held for the community in 2019 included such topics as:

- 5 Ask About Lung Health prevention program
- 61 Quit Smoking prevention program
- Cancer: Thriving & Surviving (6 week educational program)
- Palliative Care for the Cancer Patient educational program
- Ladies Night Out educational program

Our cancer patients have convenient and easy access to:

- Diagnosis, treatment and follow-up that can only be found at an NCI designated treatment facility
- Clinical research and experimental treatments for advanced cancers
- The expertise and insight of oncologist from a renowned facility
- Support personnel with expertise in the care and treatment of cancer patients
- Oncology Certified Nursing Staff
- Dedicated Clinical Research Nurse

Clinical Research

A primary objective for Rutgers CINJ Hamilton is to participate in clinical research trials that are conducted for the purpose of improving patient care and ultimate survival. Year-to-date 11/1/2018, 167 patients were accrued to clinical trials.

Cancer Prevention Program

The cancer committee organized one lung cancer prevention program designed to reduce the incidence of a specific cancer type and targeted to meet the prevention needs of the community. “Ask About Lung Health” prevention program is consistent with ACS evidence-based national guidelines for cancer prevention. The program was offered to the surrounding community on July 8, 2019. The program discussed lung health, smoking cessation and lung cancer diagnosis. The program had eight attendees. The attendees were provided a short evaluation. 100% of the attendees found a benefit in the program. 88% of the attendees found that they increased their knowledge of lung health. 75% of the participants reported that they would refer a family or friend to attend a future program.

Cancer Screening Program

The cancer committee offered a prostate cancer screening program to the surrounding community on February 11, 2019 at the Cancer Center, Hamilton that is designed to decrease the number of patients with late-stage prostate cancer. The screening program is consistent with ACS evidence-based national guidelines. Ten attendees attended the session. The program objective discuss diagnosis, treatment, and survivorship. Three of the ten participants were found to have a PSA higher than the recommended 3.0 level. These participants were provided with their PSA lab value. The formal process developed to follow up on all positive findings recommended that the participant be referred to an Urologist for more definitive care. Participants were provided a short evaluation. Findings from the evaluation indicated that the participants were 100% satisfied with the program and found value in the session. 100% of the participants noted increase in awareness of prostate cancer.

Monitoring Compliance with Evidence-Based Guidelines

The cancer committee designates a physician member to complete an in-depth analysis to assess and verify that cancer program patients are evaluated and treated according to evidence-based national treatment guidelines. Dr. Firas Eladoumikhachi performed a retrospective review of Stage III colon cancer to determine if the patient received appropriate cancer care based on NCCN guidelines. Review of 2015-2018 analytic colon cancer was selected and found to have nineteen cases identified met the criteria. 14/19 (74%) met the NCCN guidelines for treatment. 5/19 (26%) received the recommended chemotherapy but did not complete the recommended treatment period with no documentation that we could find for the reason for stopping treatment. In conclusion, the rate of compliance with NCCN guidelines for systemic therapy of stage III colon cancer was 74% over the period of study from 1/2015 to 12/2018. Dr. Eladoumikhachi recommendation was felt that continued monitoring is recommended, and a repeat of this study for the next 3 years would be helpful.


Tumor Board Conferences

Multidisciplinary Tumor Board conferences are held the first Thursday, third Wednesday, and the second and fourth Tuesday of each month at 12 noon for physicians, nurses, allied health professionals, and clinical staff involved in the management of cancer patients. Case presentations include a review of the patient's history, physical findings, and clinical course of disease, radiographic studies and pathology slides. Each case is staged using AJCC staging, and members present discuss prospective treatment and management options based on NCCN guidelines. Year-to-date 11/1/2018, a total of 237 prospective cases were discussed at the RWJUH Tumor Board Conferences.


Tumor Registry Report

Central to the oncology program at RWJUH is the Tumor Registry. The cancer specific registry is designed to track the diagnosis, treatment and survival of each cancer patient. A complete database is maintained using METRIQ software for those diagnosed and/or treated for cancer with details on survival information for all cases. Since January 1, 1995, the registry has accessioned 16,927 cases which includes all newly diagnosed cancer cases, previously diagnosed cancer cases, and patients with a history of cancer. In 2018, the registry accessioned 797 new cancer cases of that 499 cases were analytic. 76.15% of the 499 analytic cases accessioned in

2018 were Mercer County residents, 14.63% were from Burlington County, 3.61% from Ocean County, 2% from Middlesex County and 1.40 from Monmouth County and 2.20% from other counties.



The top five analytic sites at RWJUHJ include breast, lung, colorectal, bladder, and prostate. Our data is electronically reported monthly to the New Jersey Department of Health and Senior Services State Cancer Registry (NJSCR). Each case includes data on demographics, social, family, and medical history, histology, therapeutic information, treatment, TNM staging, and SEER Summary Staging. The status of patients are checked annually to assure continued medical surveillance and to provide meaningful end results data.



Date presented at Cancer Committee: 11/13/2019